Immunotherapy

Positive results in first-in-U.S. trial of CRISPR-edited immune cells

Genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology, then infusing those cells back into the patient appears safe and feasible based on early data from the first-ever clinical trial to test the approach in humans in the United States.

Penn Today Staff